U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H23NO5
Molecular Weight 345.3896
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRETOQUINOL

SMILES

COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC

InChI

InChIKey=RGVPOXRFEPSFGH-AWEZNQCLSA-N
InChI=1S/C19H23NO5/c1-23-17-7-11(8-18(24-2)19(17)25-3)6-14-13-10-16(22)15(21)9-12(13)4-5-20-14/h7-10,14,20-22H,4-6H2,1-3H3/t14-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.situsobat.com/2014/04/inolin-tablet-3-mg.html www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf

Trimetoquinol hydrochloride dilates bronchial muscle selectively by stimulating Beta 2-receptors. It is used for the relief of bronchoconstriction associated with bronchitis, asthmatic bronchitis and bronchial asthma. Since the concurrent use of the drug with catecholamines such as Epinephrine and Isoproterenol may induce arrythmia or cardiac arrest in some cases, concurrent use is not recommended. Adverse reactions : Palpitation may occur occasionally, and alteration of blood pressure and precordial pain may appear rarely; headache may occur occasionally; tremor, dizziness, feverish sensation may also be encountered in a rare incidence; occasionally, nausea and anorexia may appear.

Originator

Yamato, E.|Hirakura, M.|Sugasawa S.
3
Curator's Comment: Mitsubishi Tanabe Pharma Corporation transferred the marketing rights of Inolin (Ingredient – Trimetoquinol) to its subsidiary, Tanabe Seiyaku Hanbai Co.Ltd at April 1, 2011. http://www.mt-pharma.co.jp/e/release/nr/2011/pdf/e_110307.pdf

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 7.34 null [pKi]
Agonist
2752
 6.49 null [pKi]
Agonist
2752
 5.43 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
Inolin

Approved Use

It is given as the bronchodilating agent in the management of reversible airways obstruction, as in asthma.
Chronic obstructive pulmonary disease
175
Sources: www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf
 Palliative
Approved
8583
Inolin

Approved Use

It is given as the bronchodilating agent in the management of reversible airways obstruction, as in chronic obstructive pulmonary disease.
Palliative
Approved
8583
Inolin

Approved Use

It is used to treat chronic bronchitis.
PubMed

PubMed

TitleDatePubMed
Errors in opioid prescribing: a prospective survey in cancer pain.
2010-04
Eyelid localization in mantle cell lymphoma: long-lasting complete remission after surface brachytherapy.
2009-08-20
Plasma and urinary concentrations of trimetoquinol by LC-MS-MS following intravenous and intra-tracheal administration to horses with heaves.
2008-12
The effect of botulinum toxin type A on full-face intense pulsed light treatment: a randomized, double-blind, split-face study.
2008-08
[Yersinia psuedotuberculosis septicemia in a healthy young woman].
2008-03
Identification and characterization of a novel peptide ligand of Tie2 for targeting gene therapy.
2008-03
Trimetoquinol: bronchodilator effects in horses with heaves following aerosolised and oral administration.
2007-05
Intravenous and intratracheal administration of trimetoquinol, a fast-acting short-lived bronchodilator in horses with 'heaves'.
2006-11
Endoscopic video-assisted breast surgery: procedures and short-term results.
2006-08
1-Benzyl-1,2,3,4-tetrahydroisoquinoline-6,7-diols as novel affinity and photoaffinity probes for beta-adrenoceptor subtypes.
2006-03-15
Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration: a prospective trial.
2006-02
Single-incision, minimally invasive total hip arthroplasty: length doesn't matter.
2004-12
Beta-adrenoreceptor agonists for diffuse esophageal spasm.
2002
Biochemical activities of trimetoquinol analogs at human beta(1)- and beta(3)-adrenergic receptors.
2001-01
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
2001

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Intravenous and intratracheal administration of trimetoquinol are tested also: http://www.ncbi.nlm.nih.gov/pubmed/17124848 http://www.ncbi.nlm.nih.gov/pubmed/17124848 http://www.ncbi.nlm.nih.gov/pubmed/963963 http://www.ncbi.nlm.nih.gov/pubmed/971582
3-12 mg per day (in 2-3 separate doses)
Route of Administration: Oral
In Vitro Use Guide
Pre-incubation of platelet microsomes with Trimethoquinol (10-100 ug/ml) for up to 4 min didn’t suppress production of Thromboxane A2-like activity.
Name Type Language
TRETOQUINOL
INN   WHO-DD  
INN  
Official Name English
tretoquinol [INN]
Preferred Name English
Tretoquinol [WHO-DD]
Common Name English
S-(-)-TRETOQUINOL
Common Name English
TRETOQUINOL, (-)-
Common Name English
6,7-ISOQUINOLINEDIOL, 1,2,3,4-TETRAHYDRO-1-((3,4,5-TRIMETHOXYPHENYL)METHYL)-, (1S)-
Systematic Name English
(-)-TRETOQUINOL
Common Name English
(-)-1,2,3,4-TETRAHYDRO-1-(3,4,5-TRIMETHOXYBENZYL)ISOQUINOLINE-6,7-DIOL
Systematic Name English
TRIMETHOQUINOL
Common Name English
Classification Tree Code System Code
WHO-ATC R03AC09
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
WHO-ATC R03CC09
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
NCI_THESAURUS C48149
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
WHO-VATC QR03CC09
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
NCI_THESAURUS C319
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
WHO-VATC QR03AC09
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
Code System Code Type Description
DRUG CENTRAL
2723
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
EPA CompTox
DTXSID7023695
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
PUBCHEM
65772
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
ChEMBL
CHEMBL299175
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
NCI_THESAURUS
C66629
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
FDA UNII
JIO3275WGI
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
INN
2648
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
EVMPD
SUB11248MIG
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
CAS
30418-38-3
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
MESH
D014213
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
WIKIPEDIA
TRETOQUINOL
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
DRUG BANK
DB13692
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
SMS_ID
100000077508
Created by admin on Mon Mar 31 18:14:29 GMT 2025 , Edited by admin on Mon Mar 31 18:14:29 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of TRETOQUINOL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966